Connect Biopharma (CNTB) analyst forecast and price target
Analyst forecast
Consensus of 8 analyst ratings
Based on 5 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Leerink Partners | Initiated Coverage | Outperform | $4.00 | Oct 12, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Oct 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Oct 2, 2026 |
| BTIG | Maintained | Buy | $5.00 from $10.00 | Sep 30, 2026 |
| Oppenheimer | Maintained | Outperform | $5.00 from $8.00 | Sep 22, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Sep 17, 2026 |
| Canaccord Genuity | Maintained | Buy | $6.00 from $7.00 | Sep 16, 2026 |
| BTIG | Maintained | Buy | $10.00 | Sep 15, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $8.00 | Jul 9, 2026 |
| Piper Sandler | Initiated Coverage | Neutral → Overweight | $7.00 | Jun 26, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Jun 25, 2026 |
| Canaccord Genuity | Initiated Coverage | Buy | $6.00 | May 26, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $4.00 | May 21, 2026 |
| BTIG | Maintained | Buy | $10.00 | Apr 1, 2026 |
| BTIG | Maintained | Buy | $10.00 | Mar 31, 2026 |
| Lake Street | Initiated Coverage | Buy | $9.00 | Dec 1, 2025 |
| BTIG | Maintained | Buy | $10.00 | Nov 13, 2025 |
| BTIG | Initiated Coverage | Buy | $10.00 | Oct 31, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Aug 13, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $7.00 | Jun 12, 2025 |
Frequently asked questions
What is the price target for CNTB stock?
The average 12-month analyst price target for Connect Biopharma (CNTB) is $5.40, with a high estimate of $7.00 and a low of $4.00, across 5 analysts.
Is CNTB a buy, sell, or hold?
Analysts covering Connect Biopharma currently average a Buy rating: 8 buy, 0 hold and 0 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for CNTB?
The average price target of $5.40 implies 487.72% upside from the last price of $0.92.
What is the latest analyst rating on CNTB?
On Oct 12, 2026, Leerink Partners initiated coverage of Connect Biopharma at Outperform with a price target of $4.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.